Bioverativ climbs on board Bicycle’s peptide platform in discovery deal; Ironwood CFO jumps ship, joins Vertex

⇨ Biogen spinout Bioverativ is collaborating with Bicycle Therapeutics on new hemophilia and sickle cell disease peptide therapies. The deal comes with $10 million up front and $4.2 million for research support. Then there’s $410 million in milestones that add up for a string of potential successes.

⇨ Tom Graney is jumping ship at Ironwood $IRWD and moving over to Vertex $VRTX as its new CFO.

⇨ Avadel Pharmaceuticals is fronting $50 million for licensing rights to Noctiva, a drug for nocturia due to nocturnal polyuria.

⇨ MEI Pharma {MEIP} has forged a licensing pact with Presage Biosciences for voruciclib, an oral and selective cyclin-dependent kinase inhibitor. Under the terms of the agreement, MEI Pharma receives exclusive worldwide rights to develop, manufacture and commercialize voruciclib and Presage will receive near-term payments of $2.9 million and additional potential payments of up to $181 million.

⇨ Struggling San Diego-based MabVax $MBVX has engaged some help in exploring its strategic alternatives.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->